A Two-Part, Non-Randomised, Open Label Study to Evaluate the Effect of Itraconazole, Rifampicin, Rabeprazole, and Omeprazole on the Pharmacokinetics of KD025
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2018
At a glance
- Drugs KD 025 (Primary) ; Itraconazole; Rabeprazole; Rifampicin
- Indications Graft-versus-host disease; Idiopathic pulmonary fibrosis; Plaque psoriasis; Scleroderma
- Focus Pharmacokinetics
- Sponsors Kadmon Corporation
- 11 Oct 2018 Number of treatment arms has been increased hence number of patients has also increased. Endpoints has also added.
- 11 Oct 2018 Planned number of patients changed from 40 to 78.
- 11 Oct 2018 Planned End Date changed from 20 Jul 2018 to 15 Jun 2019.